Last reviewed · How we verify
DTaP Vaccine A
DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens.
DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children.
At a glance
| Generic name | DTaP Vaccine A |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated diphtheria and tetanus toxoids (toxins rendered non-toxic) and acellular pertussis antigens that trigger both humoral and cell-mediated immune responses. This priming of the adaptive immune system enables the body to recognize and neutralize these pathogens upon future exposure, preventing disease.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fussiness or irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP Vaccine A CI brief — competitive landscape report
- DTaP Vaccine A updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI